These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2140113)

  • 1. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
    Hassanzadeh MK; Aweeka FT; Wu S; Jacobson MA; Gambertoglio JG
    J Chromatogr; 1990 Jan; 525(1):133-40. PubMed ID: 2140113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.
    Pettersson KJ; Nordgren T; Westerlund D
    J Chromatogr; 1989 Mar; 488(2):447-55. PubMed ID: 2526150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of foscarnet (trisodium phosphonoformate) in pharmaceutical preparations by high-performance liquid chromatography with ultraviolet detection.
    García J; Márquez A; Ruiz R; López LF; Claro C; Lucero MJ
    Biomed Chromatogr; 2006 Oct; 20(10):1024-7. PubMed ID: 16583452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.
    Klintmalm G; Lönnqvist B; Oberg B; Gahrton G; Lernestedt JO; Lundgren G; Ringdén O; Robert KH; Wahren B; Groth CG
    Scand J Infect Dis; 1985; 17(2):157-63. PubMed ID: 2992074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
    Lankelma J; Penders PG; Leyva A; Pinedo HM
    Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
    Ahlmén J; Wijnween AC; Brynger H; Lycke E
    Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
    Ganly PS; Arthur C; Goldman JM; Schulenburg WE
    Postgrad Med J; 1988 May; 64(751):389-91. PubMed ID: 2849092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foscarnet prophylaxis in marrow transplant recipients.
    Ringden O; Lonnqvist B; Aschan J; Sundberg B
    Bone Marrow Transplant; 1989 Nov; 4(6):713. PubMed ID: 2555006
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.
    Reusser P; Gambertoglio JG; Lilleby K; Meyers JD
    J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
    Jacobson MA; Gambertoglio JG; Aweeka FT; Causey DM; Portale AA
    J Clin Endocrinol Metab; 1991 May; 72(5):1130-5. PubMed ID: 1827127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
    Chrisp P; Clissold SP
    Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation.
    Locke TJ; Odom NJ; Tapson JS; Freeman R; McGregor CG
    J Heart Transplant; 1987; 6(2):120-2. PubMed ID: 3040944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cytomegalovirus infection.
    Reed EC; Meyers JD
    Clin Lab Med; 1987 Dec; 7(4):831-52. PubMed ID: 2446819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.
    Knox KK; Drobyski WR; Carrigan DR
    Lancet; 1991 May; 337(8752):1292-3. PubMed ID: 1674092
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
    Ringdén O; Lönnqvist B; Paulin T; Ahlmén J; Klintmalm G; Wahren B; Lernestedt JO
    J Antimicrob Chemother; 1986 Mar; 17(3):373-87. PubMed ID: 3009383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology: foscarnet.
    Lietman PS
    Am J Med; 1992 Feb; 92(2A):8S-11S. PubMed ID: 1371039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.
    Tatarowicz WA; Lurain NS; Thompson KD
    J Infect Dis; 1992 Oct; 166(4):904-7. PubMed ID: 1326585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
    Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B
    Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
    Barton SE; Munday PE; Kinghorn GR; van der Meijden WI; Stolz E; Notowicz A; Rashid S; Schuller JL; Essex-Cater AJ; Kuijpers MH
    Genitourin Med; 1986 Aug; 62(4):247-50. PubMed ID: 2942457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
    Weber JN; Thom S; Barrison I; Unwin R; Forster S; Jeffries DJ; Boylston A; Pinching AJ
    Gut; 1987 Apr; 28(4):482-7. PubMed ID: 3034745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.